Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
7.10.2019 15:30:00 EEST | Business Wire | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.
Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.
“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.
“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005221/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Marni Kottle, Media
(650) 522-5388
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlightSafety International and Honda Aircraft Company Partner to Offer New Course to HA-420 Pilots20.10.2026 19:00:00 EEST | Press release
FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an expansion of its longstanding partnership with Honda Aircraft Company to provide a new Runway Operations Mastery course for HA-420 Elite and Elite II pilots. Developed in collaboration with Honda Aircraft Company, the immersive training course focuses on strengthening pilot proficiency to support safer operations. The new voluntary offering reflects the companies’ shared commitment to advancing aviation safety through specialized training. “For more than 75 years, FlightSafety’s mission has been to advance aviation safety through training that addresses real-world challenges pilots face,” said Ben Carter, Executive Vice President, Learning Center Operations, FlightSafety International. “This new course reflects our ongoing commitment to working with our OEM partners to deliver specialized training that reinforces critical skills to support more confident decision-
TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform20.10.2026 18:00:00 EEST | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced today the introduction of its Cessna Grand Caravan EX Veris Virtual Reality Flight Training Device (FTD), expanding the Veris product line to support one of the aviation industry's most versatile and widely utilized aircraft platforms. The announcement marks the first Caravan-configured training device offered within TRU Simulation's portfolio and reflects the company's continued investment in immersive aviation training technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020834162/en/ TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform "The Veris platform was created to make high-fidelity simulation accessible to more operators and training organizations, helping to meet the growing need for efficient pilot training and proficiency development ac
Xceedance Named a Leader and Star Performer in Everest Group’s Insurance Intermediaries Operations PEAK Matrix ® Assessment 202620.10.2026 17:00:00 EEST | Press release
Xceedance today announced it has been named a Leader and Star Performer in the Everest Group Insurance Intermediaries Operations PEAK Matrix® Assessment 2026. The assessment evaluated 18 providers based on market impact and their vision and capability to deliver insurance intermediary operations services. Everest Group identified Xceedance’s support for MGAs and MGUs across entity setup and licensing, underwriting, policy administration, finance, analytics, and claims as a key strength. The report also highlighted enabling rapid program launches and scaling through a licensed MGA shell, configurable workflows, and integrated operations. “Xceedance brings deep insurance expertise and a growing breadth of capabilities to support MGAs, brokers, and Lloyd’s market participants,” said Dinesh Udawat, Practice Director, Everest Group. “Its strategic acquisitions have expanded its agent and broker capabilities, while continued investments in AI and insurance-specific technology are enabling mo
92% of Compliance Leaders Want External Certification on AI Agents. None Exists for On-Chain Risk. Elliptic Just Built It, for Free.20.10.2026 17:00:00 EEST | Press release
Elliptic, the leader in on-chain risk management, today launched the first certification in governing AI agents for on-chain risk and financial crime compliance from the Elliptic Institute. The Certified Agentic On-Chain Risk Practitioner (CAORP) Foundation Level is free and open to anyone in the industry. The certification follows new Elliptic research in which 92% of senior risk, compliance and financial crime professionals said they would consider sending staff for external certification in agentic AI risk governance. The global research1 found a wide gap between that appetite and teams' current capability. Only 16% of respondents said they were very confident their team has the skills to govern an AI agent today, while 38% said they were not confident at all or had no capability yet. Nearly a third (31%) expect to send staff for certification within the next 12 months. The demand for training has arrived well ahead of anywhere to get it. The timing isn't optional. The EU AI Act now
Andersen Consulting Adds Collaborating Firm in Uzbekistan20.10.2026 16:30:00 EEST | Press release
Andersen Consulting expands its cybersecurity and business transformation capabilities through a Collaboration Agreement with Algoruni, a consulting firm based in Uzbekistan. Algoruni advises organizations on building cyber resilience, while addressing broader management, regulatory, and sustainability priorities. Operating out of Tashkent, the firm’s services span cybersecurity strategy and data protection, corporate governance and operational improvement, and ESG strategy and reporting, with an emphasis on practical solutions tailored to each client’s circumstances. “Every organization faces a different combination of risks and opportunities, which is why we believe effective solutions must start with the realities of the business,” said Alisher Zaynutdinov, managing director of Algoruni. “Becoming a collaborating firm of Andersen Consulting allows us to pair this approach with broader international resources and perspectives, giving us new ways to help clients turn complex challenge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom